A prospective survey of the use of dexamethasone on a palliative care unit

Hardy, J.R.; Rees, E.; Ling, J.; Burman, R.; Feuer, D.; Broadley, K.; Stone, P.
January 2001
Palliative Medicine;Jan2001, Vol. 15 Issue 1, p3
Academic Journal
One hundred and six consecutive patients started on glucocorticosteroids (steroids) according to a defined prescription policy were surveyed each week to document the indications for use, any beneficial effect, any toxicity incurred and the reason for stopping. All patients had advanced malignant disease and survived for a median of 40.5 days (range 1-398 + days) from the start of steroid treatment. Fifty-seven per cent of patients completed three or more assessments. The most common specific indications for starting steroids were spinal cord compression, cerebral metastases, lymphangitis carcinomatosa and intestinal obstruction. The most common non-specific indications were anorexia, nausea, low mood, pain and vomiting. The median duration of steroid use was 21.5 days (range 1-89 days). The most common reason for the discontinuation of steroids was death or deteriorating condition. Symptom scores improved at some stage for the majority of patients started on steroids for anorexia, nausea, pain, low mood, vomiting and weakness but not in patients complaining of dyspnoea or poor mobility. The most common side-effects that were most probably attributable to steroid therapy were oral candidosis and proximal myopathy. The benefits of steroids when used according to defined guidelines were thought to outweigh toxicity.


Related Articles

  • RESEARCH.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/16/2011, Vol. 342 Issue 7802, p855 

    No abstract available.

  • Case Report: Relieving the Itch of Cholestasis with Corticosteroids in Palliative Care. Berger, Liora; Garcia Popov, Andrei; Berger, Brian // Journal of Palliative Medicine;Nov2015, Vol. 18 Issue 11, p913 

    The article describes the case of a patient who are diagnosed with cholestasis. Topics covered include the use of corticosteroids in patients who are involved in a palliative care setting. Also mentioned is the successful use of cholestasis treatments including rifampicin and hydroxyzine in...

  • The existential impact of starting corticosteroid treatment as symptom control in advanced metastatic cancer. Lundström, S.; Fürst, C. J.; Friedrichsen, M.; Strang, P. // Palliative Medicine;Mar2009, Vol. 23 Issue 2, p165 

    Treatment with corticosteroids often results in increased appetite, reduced nausea and improved well-being in patients with advanced metastatic cancer. Therefore, we have studied the existential impact of starting corticosteroid treatment as symptom control in this patient group using...

  • The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Laval, G.; Girardier, J.; Lassaunière, J.; Leduc, B.; Haond, C.; Schaerer, R. // Palliative Medicine;Jan2000, Vol. 14 Issue 1, p3 

    This multicentre, randomized double-blind study was undertaken to assess the efficacy of corticosteroids as a palliative treatment of intestinal obstruction due to advanced and incurable cancer. Thirty-one French palliative care units agreed to participate in the study and 12 actually recruited...

  • Corticosteroids in palliative care - perspectives of clinicians involved in prescribing: a qualitative study. Denton, Anne; Shaw, John // BMC Palliative Care;2014, Vol. 13 Issue 1, p1 

    Background Corticosteroids are commonly prescribed in palliative care for alleviation of both specific and non-specific symptoms, but relatively little is known of the perspectives of clinicians and what influences their prescribing in this context. The aim of this study was to explore the...

  • P2–106END OF LIFE CARE AT A GYNECOLOGIC ONCOLOGY UNIT. Hasumi, Y.; Numata, A.; Kubota, K.; Tsukazaki, T.; Hashimoto, K.; Horie, K.; Yokota, H. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix84 

    No abstract available.

  • Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit. Hui, David; Li, Zhijun; Chisholm, Gary; Didwaniya, Neha; Bruera, Eduardo // Supportive Care in Cancer;Feb2015, Vol. 23 Issue 2, p427 

    Purpose: The decision-making process for medication use in the last weeks of life is complex because of patient frailty and poor prognosis. Limited literature is available on medication use in the palliative care setting, particularly in acute palliative care units (APCUs). We examined the...

  • Cutaneous presentation of hepatosplenic T-cell lymphoma-a potential mimicker of primary cutaneous gamma-delta T-cell lymphoma. Karpate, Arti; Barcena, Carmen; Hohl, Daniel; Bisig, Bettina; Leval, Laurence; de Leval, Laurence // Virchows Archiv;Nov2016, Vol. 469 Issue 5, p591 

    The article describes the case of a 62-year-old female patient with type 2 diabetes who was diagnosed with hepatosplenic T-cell lymphoma (HTSL). Particular focus is given to her medical history, as well as symptoms. Results of her physical examination include ulcers in the buccal cavity and...

  • NSAIDs: gastroprotection or selective COX-2 inhibitor? Dickman, Andrew; Ellershaw, John // Palliative Medicine;Jul2004, Vol. 18 Issue 4, p275 

    Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are effective adjuvant analgesics commonly encountered in palliative care. However, these drugs are associated with adverse effects that are primarily due to gastrointestinal toxicity, with resultant serious complications such as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics